---
title: Light Made a Cancer Drug Up to 96 Times More Potent in the Lab
description: A study finds light can make the cancer drug CX-5461 up to 96 times more potent and, in mice, trigger a vaccine-like immune response.
author: Darie Nani (Editor-in-Chief)
date: 2026-08-12T12:00:00.000Z
updated: 2026-09-25T01:01:22.416Z
canonical: https://richhealthmagazine.com/article/light-made-a-cancer-drug-up-to-96-times-more-potent-in-the-lab
image: https://cdn.nanimediahouse.com/senhwa-light-cancer-drug-143707.webp
categories: Longevity & Science
content_type: News
region: Global
publication: Rich Health Magazine
schema_type: Article
---

In lab dishes, shining a specific wavelength of light on an investigational cancer drug made it dramatically better at killing tumor cells, and in mice, that same light trigger also set off an immune response that behaved like a vaccine against the cancer.

The finding, published in the journal Nucleic Acids Research, centers on CX-5461, also known as Pidnarulex, a drug already in clinical trials for other cancers. It is being developed by Senhwa Biosciences, a Taiwan-based oncology biotech, and carries an FDA Fast-Track designation. For years, one property of CX-5461 was treated mainly as a nuisance to manage during trials: it reacts to light. The new study, led by an international team from Wroclaw University of Science and Technology in Poland, the Slovak Academy of Sciences, ENS de Lyon in France, and Senhwa, asked whether that reactivity could be used on purpose, as a switch to activate the drug where it is wanted.

## Researchers Turned a Known Side Effect Into a Targeting Tool

The researchers exposed CX-5461 to 365 nanometer light, a wavelength in the near-ultraviolet range, while the drug was bound to structures in cancer-cell DNA called G-quadruplexes. Under those conditions, its ability to kill CT26 colon cancer cells rose by up to 96-fold compared with cells kept in the dark, according to the study. The light does not make the drug stronger everywhere. It appears to redirect the drug's chemistry toward a more destructive, radical-driven attack on cancer cells where the light reaches.

A drug's sensitivity to light is normally something trials try to control, since it can cause unpredictable reactions in skin or tissue exposed to sunlight. Here the same property becomes a form of precision. Because CX-5461 can be switched on with light at a chosen location, the researchers say it could one day be delivered to a specific site, using external light, endoscopy or fiber-optic tools, and activated only there. The company points to skin, oral and esophageal tumors as targets light can reach directly, killing illuminated tumor tissue while leaving tissue outside the light's path largely undisturbed.

## Mice Developed Lasting Immune Memory After Treatment

The effect reached beyond killing cells directly. In mouse models of [colon cancer](https://richhealthmagazine.com/article/high-fat-diet-colon-cancer-liver-spread-mice) and melanoma, light-activated CX-5461 triggered a process called immunogenic cell death, in which dying tumor cells release signals, including a protein called HMGB1 and a marker called calreticulin on their surface, that alert the immune system. The study documented activation of dendritic cells and a rise in CD8+ T cells, the immune system's tumor killers, moving into the treated tumors. The treated mice showed slower tumor growth and longer survival.

The researchers then took mice whose tumors had regressed and exposed them again to the same cancer cells. Tumor growth was suppressed the second time too, a pattern consistent with immune memory. The team describes this as an early step toward an in situ cancer vaccine, in which a patient's own tumor, once treated with light, could teach the immune system to recognize and fight the cancer elsewhere in the body. They note the approach could eventually be paired with checkpoint inhibitor drugs that target PD-1 or PD-L1, a combination they have not yet tested.

## The Findings Are Preclinical, With Human Trials Years Away

None of this has been tested in people as a light-based treatment. The results come from cell cultures and mouse models, and the researchers are explicit that the approach needs confirmation in further animal studies before any human trials could begin. CX-5461 itself is already in active Phase I and Phase II trials for other cancer uses, but its safety and effectiveness as a light-activated, or photodynamic, therapy have not been established in people. Light-activated therapies that target G-quadruplex DNA have been studied for roughly a decade, so this work sits inside an established research field rather than standing alone, though that field as a whole remains preclinical.

## FAQ

**Q: Is this treatment available to patients yet?**
No. The findings are preclinical, based on cell cultures and mouse studies. The researchers say further animal studies and human clinical trials are needed before light-activated use could be tested in people.

**Q: What is CX-5461 (Pidnarulex)?**
It is an investigational cancer drug, also known by the lab code CX-5461, originally developed as an inhibitor of a cellular machine called RNA polymerase I and as a stabilizer of DNA structures called G-quadruplexes. It is currently in Phase I and Phase II clinical trials for other cancer applications and holds FDA Fast-Track designation.

**Q: What is immunogenic cell death?**
It is a way cancer cells can die that alerts the immune system rather than going unnoticed. Dying cells release or expose specific molecules that activate immune cells, including dendritic cells and T cells, which can then recognize and attack similar cancer cells elsewhere.

**Q: What is photoimmunotherapy, and is this the same as an approved treatment?**
Photoimmunotherapy uses light to activate a drug at a specific location, aiming to combine direct tumor killing with an immune response. It is an active but still emerging research field. This study is an early laboratory and mouse demonstration, not an approved or clinically tested therapy.